Skip to main content
Sign In

Chrisopher C. Striebich MD, PHD

Assistant Professor

Dr. Striebich heads or clinical trials section and is currently pursuing mechanism-based clinical trials. Projects are underway investigating the efficacy and mechanisms of effect of new biologic agents in multiple autoimmune diseases including RA, SLE, psoriatic arthritis and other inflammatory diseases. Dr. Striebich also acts as head of the Division's program entitled 'EPIC' (Every Patient Improving Care). This program is designed to maximize patients' contributions to the advancement of rheumatologic research.

1997-1999 Instructor/Fellow Division of Rheumatology, Department of Medicine, University of Colorado Denver, Denver, CO
1994-1997 Fellow Division of Rheumatology, Department of Medicine, University of Colorado Denver, Denver, CO
1991-1994 Resident Department of Medicine University of Colorado Denver, Denver, CO
Medical School University of Texas Medical Branch, Galveston, Texas
2002-Present Assistant Professor Director of Clinical Trials, Division of Rheumatology,     Department of Medicine University of Colorado Denver, Denver, CO
1999-2002 Associate Physician Sansum-Santa Barbara Medical Foundation Clinic, Inc.,    Santa Barbara, CA
1994-1996 Smyth Fellowship for Research in the Rheumatic Diseases, University of Colorado Denver
1988 James W. McLaughlin Travel Award, University of Texas Medical Branch
1987-1989 James W. McLaughlin Predoctorial Fellowship in Infection and Immunity University of Texas Medical Branch
1982 Graduate with High Honors University of California Santa Barbara
1980 Alpha Gamma Sigma Honor Scholarship El Camino College
1980 El Camino College Academic Achievement Award Physical Sciences
1979 Freshman Chemistry Award El Camino College

Description in a couple of paragraphs about research interests and/or clinical trial interests:

My research interests center on the application of new therapeutics in the treatment of rheumatic diseases. As our understanding of the function of the immune system in autoimmune disease has increased, the potential for intervention in the disease process has also increased. Several novel therapeutics have been developed which have been shown to disrupt the autoimmune process and so modify the pathologic manifestations of disease in experimental animal models. These therapeutics (often referred to as biologics) include monoclonal antibodies to cell surface antigens or to cytokines, as well as soluble receptor fusion proteins. However, these novel therapies must be evaluated in patients through the use of controlled clinical trials to determine not only the safety but also the efficacy of these therapies. Such trials also provide an opportunity to further evaluate the immune mechanisms by which the interventions operate in human subjects that may differ from those in the animal models. We are actively expanding our clinical trials program through both traditional pharmaceutical company initiated research protocols (which provide access to patented therapeutics that may not otherwise be available for clinical research) and through NIH funded, investigator initiated, protocols.

6-8 representative publications:

  1. Striebich, C. C., M. T. Falta, Y. Wang, J. Bill, and B.L. Kotzin. 1998. Selective accumulation of related CD4+ T cell clones in the synovial fluid of patients with rheumatoid arthritis. J. Immunol. 161:4428.
  2. Striebich, C. C., R. M. Miceli, D.H. Schulze, G. Kelsoe, and J. Cerny. 1990. Antigen-binding repertoire and Ig H chain gene usage among B cell hybridomas from normal and autoimmune mice. J. Immunol. 144:1857.